BiPar Sciences Report issue

For profit Phase 2
Founded: Brisbane CA United States (2002)
Status: Acquired by Sanofi-Aventis (2009)

Organization Overview

First Clinical Trial
2007
NCT00540358
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (3)

carboplatin (paraplatin) (1 trial)

gemcitabine (gemzar) (1 trial)

iniparib (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 3